LifeVantage granted third patent for Protandim
San Diego-based LifeVantage Corp. (OTC: LFVN), has been granted a third patent for its flagship product Protandim.
Protandim has been clinically proven in earlier studies to slow the progressive rate of aging by reducing oxidative stress.
This new patent further documents Protandim’s effect on antioxidant enzymes in vivo, describing anti-inflammatory effects such as the lowering of C-reactive protein.
C-reactive protein is widely considered by doctors and researchers as an indicator of the amount of inflammation present in the body. Elevated basal levels of C-reactive protein are considered risk factors for diabetes, hypertension, and cardiovascular disease.
The patent, “Methods for Enhancing Antioxidant Enzyme Activity and Reducing C-Reactive Protein Levels,” was issued Aug. 25